Cargando…

Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy

PURPOSE: The aim of this study is to assess baseline mean leukocyte telomere length (TL) as a potential predictive factor for chemotherapy toxicity and a prognostic marker for long-term outcome in early breast cancer (BC) patients. METHODS: 445 BC patients were selected, diagnosed between 2007 and 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hatse, Sigrid, Serena, Marta, Vulsteke, Christof, Punie, Kevin, Neven, Patrick, Smeets, Ann, Laenen, Annouschka, Wildiers, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558049/ https://www.ncbi.nlm.nih.gov/pubmed/36219936 http://dx.doi.org/10.1016/j.tranon.2022.101551

Ejemplares similares

Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy
por: Dalmasso, Bruna, et al.
Publicado: (2018)

Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty
por: Bailur, Jithendra Kini, et al.
Publicado: (2017)

Dynamic alterations of immunosenescence-related genes in older women with breast cancer receiving chemotherapy: A prospective study
por: Wu, Qi, et al.
Publicado: (2022)

The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters
por: Brouwers, Barbara, et al.
Publicado: (2016)

Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors
por: Pfeil, Alena M, et al.
Publicado: (2014)

Biological ageing and frailty markers in breast cancer patients
por: Brouwers, Barbara, et al.
Publicado: (2015)

Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer
por: Lambrechts, Yentl, et al.
Publicado: (2023)

Age‐related remodelling of the blood immunological portrait and the local tumor immune response in patients with luminal breast cancer
por: Berben, Lieze, et al.
Publicado: (2020)

Circulating MicroRNAs as Easy-to-Measure Aging Biomarkers in Older Breast Cancer Patients: Correlation with Chronological Age but Not with Fitness/Frailty Status
por: Hatse, Sigrid, et al.
Publicado: (2014)

Tumor Glucose and Fatty Acid Metabolism in the Context of Anthracycline and Taxane-Based (Neo)Adjuvant Chemotherapy in Breast Carcinomas
por: Tőkés, Anna Mária, et al.
Publicado: (2022)

Changes in leukoencephalopathy and serum neurofilament after (neo)adjuvant chemotherapy for breast cancer
por: Schroyen, Gwen, et al.
Publicado: (2023)

Correlation of TROP-2 expression with clinical–pathological characteristics and outcome in triple-negative breast cancer
por: Izci, Hava, et al.
Publicado: (2022)

Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3
por: De Cock, L., et al.
Publicado: (2021)

Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer
por: Mukherjee, A, et al.
Publicado: (2010)

Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Vos, Hanne, et al.
Publicado: (2021)

Advances in anthracycline chemotherapy : epirubicin /
Publicado: (1984)

Incidence of Chemotherapy-Induced Amenorrhea After Adjuvant Chemotherapy With Taxane and Anthracyclines in Young Patients With Breast Cancer
por: Pourali, Leila, et al.
Publicado: (2013)

Successful treatment of gallbladder mixed adenoneuroendocrine carcinoma with neo-adjuvant chemotherapy
por: Song, Wu, et al.
Publicado: (2012)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
por: Findlay, John M., et al.
Publicado: (2016)

Blood Immunosenescence Signatures Reflecting Age, Frailty and Tumor Immune Infiltrate in Patients with Early Luminal Breast Cancer
por: Berben, Lieze, et al.
Publicado: (2021)

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
por: Slagter, Astrid E., et al.
Publicado: (2018)

Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)
por: Dikken, Johan L, et al.
Publicado: (2011)

Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients
por: Mina, Alain, et al.
Publicado: (2015)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
por: Chen, Wanjing, et al.
Publicado: (2021)

Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer
por: Chang, Alex Yuang-Chi, et al.
Publicado: (2016)

Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
por: Bhattacharyya, G. S., et al.
Publicado: (2018)

Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer
por: Voutsadakis, Ioannis A.
Publicado: (2016)

Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study
por: Constantinidou, Anastasia, et al.
Publicado: (2020)

Genetic variations in triple-negative breast cancers undergoing neo-adjuvant chemotherapy
por: Mori, Miki, et al.
Publicado: (2019)

Impact of oncoplasty in increasing breast conservation rates Post neo-adjuvant chemotherapy
por: Koppiker, Chaitanyanand B., et al.
Publicado: (2023)

Differences in the Tumor Molecular and Microenvironmental Landscape between Early (Non-Metastatic) and De Novo Metastatic Primary Luminal Breast Tumors
por: Lambrechts, Yentl, et al.
Publicado: (2023)

Telomere length predicts for outcome to FCR chemotherapy in CLL
por: Norris, Kevin, et al.
Publicado: (2019)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

NEO adjuvant chemotherapy in breast cancer: What have we learned so far?
por: Raut, Nirmal V, et al.
Publicado: (2010)

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
por: Drooger, Jan C., et al.
Publicado: (2016)

Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases
por: Rossi, Luigi, et al.
Publicado: (2012)

Accuracy of MRI for prediction of response to neo-adjuvant chemotherapy in triple negative breast cancer
por: Bansal, GJ, et al.
Publicado: (2015)

Neo Adjuvant Chemotherapy on Testicular Cancer after Scrotal Exploration: A Case Report
por: Novianda, Andhika H., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dr2n7i9nragkkimkboc9u7bcei